)
Visual
earnings real time
Precision BioSciences (DTIL) investor relations material
Precision BioSciences Sidoti's Year End Virtual Investor Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Sidoti's Year End Virtual Investor Conference summary11 Dec, 2025
Strategic focus and financial position
Company is exclusively focused on two in-vivo gene editing programs: PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.
Recent $75 million financing extends cash runway through 2028, supporting clinical milestones and data readouts.
ARCUS gene editing platform has demonstrated clinical validation in multiple indications, including partnerships and internal programs.
Ongoing discussions with potential partners for commercialization, especially for the HBV program.
Company maintains a disciplined, focused approach to capital allocation and program execution.
PBGENE-HBV (Hepatitis B) program progress
PBGENE-HBV targets the root cause of hepatitis B by eliminating cccDNA, aiming for a functional cure.
Phase 1 ELIMINATE-B trial has shown dose-dependent antiviral activity and a manageable safety profile across three cohorts.
Higher dose cohorts demonstrate sustained S antigen reduction, with some patients nearing levels where cure testing is possible.
Plans to complete cohort three dosing, explore shorter dosing intervals, and expand to more patients before phase 2.
Data readouts expected at major liver conferences and throughout 2026.
PBGENE-DMD (Duchenne muscular dystrophy) program progress
PBGENE-DMD uses gene editing to excise mutations in exons 45-55, potentially benefiting up to 60% of DMD patients.
Preclinical studies show restoration of functional dystrophin protein above the 5% threshold linked to milder disease.
Function-DMB trial designed as a phase 1/2/3 study, aiming to enroll first patients in 2026 and read out data by end of 2026.
Safety is prioritized with aggressive immunomodulation and top clinical sites.
Potential for BLA filing by end of 2028 if data are positive.
S antigen level to stop nukes and test for cure?
Justify single dose level for Function DMD
Partnering strategy for HBV vs DMD programs
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Precision BioSciences earnings date
Q4 202527 Mar, 2026
Next Precision BioSciences earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Precision BioSciences Inc. is a U.S.-based biotechnology company focused on developing gene editing technologies. The company utilizes its proprietary ARCUS genome editing platform to research and develop treatments for genetic disorders and cancers. Its work spans cell and gene therapies, with applications in both in vivo and allogeneic CAR T-cell therapies. Precision BioSciences collaborates with academic institutions and pharmaceutical companies to advance its research and clinical programs. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage